# MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC

> **NCT02369198** · PHASE1 · COMPLETED · sponsor: **Asbestos Diseases Research Foundation** · enrollment: 27 (actual)

## Conditions studied

- Malignant Pleural Mesothelioma
- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** TargomiRs

## Key facts

- **NCT ID:** NCT02369198
- **Lead sponsor:** Asbestos Diseases Research Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2017-01-04
- **Final completion:** 2017-01-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02369198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02369198, "MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02369198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*